BioCryst Pharma (BCRX) Misses Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $81 million versus the consensus estimate of $81.41 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Henry Schein (HSIC) Tops Q2 EPS by 3c; raises guidance
- IDEXX Labs (IDXX) Tops Q2 EPS by 31c ; Offers Guidance
- MEDNAX (MD) Tops Q2 EPS by 3c ; Provides Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
